Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Duraiswamy J, et al. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011;30(1):141–151.,
   PubMed Web of Science ®Google Scholar
• Fleischer A, Javitt M, Jeffrey R, et al. Clinical gynecologic imaging. Philadelphia: Lippincott Williams & Wilkins; 1997.
   Google Scholar
• Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1–12.
   PubMed Web of Science ®Google Scholar
• Bast RC. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc. 2004;115:233–248.
   PubMedGoogle Scholar
• Park NJ, Zhou H, Elashoff D, et al. Salivary microrna: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15(17):5473–5477.
   PubMed Web of Science ®Google Scholar
• Li Y, John MAS, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004;10(24):8442–8450.,
   PubMed Web of Science ®Google Scholar
• Gleber-Netto FO, Yakob M, Li F, et al. Salivary biomarkers for detection of oral squamous cell carcinoma in a Taiwanese population. Clin Cancer Res. 2016;22(13):3340–3347.
   PubMed Web of Science ®Google Scholar
• Brinkmann O, Kastratovic DA, Dimitrijevic MV, et al. Oral squamous cell carcinoma detection by salivary biomarkers in a serbian population. Oral Oncol. 2011;47(1):51–55.
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Kim JH, Zhou H, et al. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma. J Mol Med (Berl). 2012;90(4):427–434.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xiao H, Karlan S, et al. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One. 2010;5(12):e15573.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xiao H, Zhou H, et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci. 2012;69(19):3341–3350.
   PubMed Web of Science ®Google Scholar
• Li F, Yoshizawa JM, Kim K-M, et al. Discovery and validation of salivary extracellular rna biomarkers for noninvasive detection of gastric cancer. Clin Chem. 2018;64(10):1513–1521.
   PubMed Web of Science ®Google Scholar
• Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010;138(3):949.e1-7–957.e1-7.
   Web of Science ®Google Scholar
• Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–146.
   PubMed Web of Science ®Google Scholar
• Wielders J, Bartels C, Bank C, et al. The diagnostic value of neuron-specific enolase and carcino-embryonic antigen analyses in patients with carcinoma of the lung. J Clin Chem Clin Biochem. 1990;28(4):225–231.
   PubMedGoogle Scholar
• Litvak A, Cercek A, Segal N, et al. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw. 2014;12(6):907–913.
   PubMed Web of Science ®Google Scholar
• Ishiba T, Hoffmann A-C, Usher J, et al. Frequencies and expression levels of programmed death ligand 1 (pd-l1) in circulating tumor rna (ctrna) in various cancer types. Biochem Biophys Res Commun. 2018;500(3):621–625.
   PubMed Web of Science ®Google Scholar
• Documentation M. Matlab r2014b fitctree; 2015. Available from: http://es.mathworks.com/help/stats/fitctree.html.
   Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:eaar3247.
   Web of Science ®Google Scholar
• Chen X, Wang X, He H, et al. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One. 2015;10(5):e0126276.
   PubMed Web of Science ®Google Scholar
• Danaee P, Ghaeini R, DA H. A deep learning approach for cancer detection and relevant gene identification. Pac Symp Biocomput. 2016;22:219–229.
   Google Scholar
• Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.
   PubMed Web of Science ®Google Scholar
• Saghapour E, Kermani S, Sehhati M. A novel feature ranking method for prediction of cancer stages using proteomics data. PLoS One. 2017;12(9):e0184203
   PubMed Web of Science ®Google Scholar
• Alakwaa FM, Chaudhary K, Garmire LX. Deep learning accurately predicts estrogen receptor status in breast cancer metabolomics data. J Proteome Res. 2018;17(1):337–347.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in brca1 and brca2 carriers. Clin Cancer Res. 2004;10(7):2473–2481.
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Gayther SA. The contribution of brca1 and brca2 to ovarian cancer. Mol Oncol. 2009;3(2):138–150.
   PubMed Web of Science ®Google Scholar
• Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in brip1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–1107.,
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. Microrna signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.
   PubMed Web of Science ®Google Scholar
• Samimi G, Fink D, Varki NM, et al. Analysis of mlh1 and msh2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res. 2000;6(4):1415–1421.
   PubMed Web of Science ®Google Scholar
• Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. JAMA. 2011;305(22):2304–2310.
   PubMed Web of Science ®Google Scholar
• Lum CT, Sun RW-Y, Zou T, et al. Gold (iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic pms2 gene. Chem Sci. 2014;5(4):1579–1584.,
   Web of Science ®Google Scholar
• Wang Z, Churchman M, Campbell I, et al. Allele loss and mutation screen at the peutz-jeghers (lkb1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer. 1999;80(1–2):70–72.
   PubMed Web of Science ®Google Scholar
• Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in brca;tp53;pten models. Cancer Cell. 2013;24(6):751–765.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in tp53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56.
   PubMed Web of Science ®Google Scholar